10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America - Wikidata - awgldk - TriplyDB

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

http://www.wikidata.org/entity/Q24601746

about

Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections The β-Lactams Strike Back: Ceftazidime-Avibactam Next-generation antimicrobials: from chemical biology to first-in-class drugs Emerging drugs and vaccines for candidemia Challenges and future in vaccines, drug development, and immunomodulatory therapy Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA Structure of shikimate kinase, an in vivo essential metabolic enzyme in the nosocomial pathogen Acinetobacter baumannii, in complex with shikimate Beyond Traditional Antimicrobials: A Caenorhabditis elegans Model for Discovery of Novel Anti-infectives Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Overcoming differences: The catalytic mechanism of metallo-β-lactamases The global threat of antimicrobial resistance: science for intervention Small molecule deubiquitinase inhibitors promote macrophage anti-infective capacity Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance.Endless Resistance. Endless Antibiotics?Chemical modulation of the biological activity of reutericyclin: a membrane-active antibiotic from Lactobacillus reuteri Excess positional mutual information predicts both local and allosteric mutations affecting beta lactamase drug resistance.High-copy bacterial plasmids diffuse in the nucleoid-free space, replicate stochastically and are randomly partitioned at cell division.Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteria Forecasting ESKAPE infections through a time-varying auto-adaptive algorithm using laboratory-based surveillance data.New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Antibiotic resistance: a public health crisis.The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.Antibiotics and bacterial resistance in the 21st century.Mechanisms of plasmid segregation: have multicopy plasmids been overlooked?Nanomedicine in the Management of Microbial Infection - Overview and Perspectives Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae.Investigational antimicrobial agents of 2013.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.The evolving role of chemical synthesis in antibacterial drug discovery.A new antibiotic and the evolution of resistance.Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.The evolution of the regulatory framework for antibacterial agents A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii.Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway.Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria.

P2860

Q26747429-3EF32EDE-DACF-4313-9CF7-DA621EC048A0 Q26796425-042D3743-5F2F-4B5A-B18C-4A6A78934D3E Q26799749-26DCA142-4CDC-4E41-A6C7-40FA51E516DA Q26828993-C8E42E8D-E501-4E75-97C4-937676418AB8 Q26853354-2B4524B2-DE47-4DF6-8534-A8EBD2DDFA45 Q26995305-BEC1AA7E-97F6-46DA-9E93-BFFD4DEE2EC1 Q27701752-3D49AB16-20CB-4D03-A8B8-41A17745469B Q28071846-4F8D6117-A8BF-4CCF-A381-6ED8FA8FFF98 Q28080607-BF047435-6DA7-491C-ABBD-2DF24CB69285 Q28082109-4A886AD6-3791-45EA-80CD-CE11DFAD4EF5 Q28083609-AE135829-BB00-4648-B942-0092BE43AE27 Q28541638-2F416BC0-DC29-44BC-8325-ED34BF3EDAAA Q28545750-295E226B-8B7E-4CDB-BFF5-8A6C95F192C3 Q28822179-66FFD3E8-71D4-40BA-A617-7658F6A62DF6 Q28828979-573B3259-34F8-4DD8-9841-70F449C72B39 Q30276256-FED6FAAE-3C8F-4B05-B3BF-4AEA9ADAB72D Q30569014-00E9AB45-6F22-452A-AF03-68F292945641 Q30576597-DE1CBF99-AF4D-4FDD-B081-047E6CCC8EFC Q30875040-969C9AE4-8B4C-4238-9FCF-AAF35696CF93 Q33622976-6E1C3994-4D11-4D88-A916-FBAC0FC6239A Q33681062-9073FCC1-9A19-4C93-9A5C-325905D5335E Q33686940-499868CB-B28A-4DE2-A5C9-E48001A8BA29 Q33792789-6B7A10F6-F11C-48D8-A08B-7C36677CE8A2 Q34156349-16E07C76-7305-476B-82CE-55D08C583B01 Q34177902-D771558C-B65C-4999-B24C-7E4093ECC8AE Q34245494-1488C7AC-B3A8-43D1-9E64-EA1FF6672294 Q34298840-37BB7853-3837-4FBE-99D6-2E8D4F22C7BF Q34372097-750DA3BD-A5C9-4F3F-9B9C-1D0A45446C6F Q34375204-190CF6D3-3940-4BAD-8A8D-A8FC760EECE7 Q34393008-CFD1A2B0-2144-40B9-A7EE-65F407E6190E Q34427652-159EB6BA-0C8D-400F-9A8B-6BECA590D424 Q34467725-6A0E0E21-350F-4C21-BB1C-4E1AC3405FE0 Q34474963-7194B0EA-9409-40F5-AC19-11A79AC35F9F Q34514304-BCA84772-683C-4F15-9243-866EA7D2DDEB Q34576222-E3AE78E5-6236-4462-96FD-14B8BE7480A8 Q34688710-602A9813-628F-43A9-B3D1-9FE203567E7F Q34693386-42EF24A1-8E14-424C-852A-D00D93B6CC9F Q34726120-735E2A3C-1437-4544-A1FD-B3CFC1F956D6 Q34922961-08C83517-9F14-460C-82AB-8A51E3014DD2 Q34982853-202E36F4-BF49-45F5-9975-5673B79D0209

P2860

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

http://www.wikidata.org/entity/Q24601746

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

10 x '20 Progress--development ...... us Diseases Society of America

@ast

10 x '20 Progress--development ...... us Diseases Society of America

@en

10 x '20 Progress--development ...... us Diseases Society of America

@nl

type

label

10 x '20 Progress--development ...... us Diseases Society of America

@ast

10 x '20 Progress--development ...... us Diseases Society of America

@en

10 x '20 Progress--development ...... us Diseases Society of America

@nl

prefLabel

10 x '20 Progress--development ...... us Diseases Society of America

@ast

10 x '20 Progress--development ...... us Diseases Society of America

@en

10 x '20 Progress--development ...... us Diseases Society of America

@nl

P1433

Q24601746-1F45F650-C16D-420A-A80F-35BE6F718305

P1476

Q24601746-9F55563E-7533-41E3-8C06-3720920C89BF

P2093

Q24601746-12F2E2DE-395B-4C5D-BE98-EB4FAE0951C8

Q24601746-454D5AAA-FBC1-41EB-8002-310EF6A68F32

Q24601746-48002339-A523-4F36-83B1-265F21C1C10D

Q24601746-63669D19-6D7A-442B-BD39-DFAA22F7BACB

Q24601746-7C29E170-8004-4F8F-99E9-1A5F2039FDF7

Q24601746-7D15C636-C457-4CCB-A535-2A4A63DA4E61

Q24601746-B59A8635-359B-439D-8360-27B6C7348BB0

Q24601746-DDE9C887-CCE9-43B2-A9A6-84CD52AEF336

P2860

Q24601746-0831F5FA-2B2B-4571-A808-CABB702C3CE9

Q24601746-0D7DE66D-1B0E-4E7C-B550-C2352B8D3106

Q24601746-12466B71-B235-400B-9B11-4A89692F04E2

Q24601746-17E59413-12B7-4224-8A02-0E08B252CAAD

Q24601746-1961556B-0648-4EC8-BBCD-B014D6932927

Q24601746-1A1A7F6B-49D8-4C8E-97FE-878444CA684C

Q24601746-1F4D3605-A6AB-476D-9DD0-94D03C815D42

Q24601746-25664942-5AEC-4C13-8CCB-3DE373ED6D17

Q24601746-28F328E2-D7A5-4CF1-9692-333163FDA3FE

Q24601746-29A812D1-43B7-432F-9B30-78974101E554

P304

Q24601746-98E04905-921E-4FFA-97B0-5431780137AB

P31

Q24601746-60AF1A47-29B2-4EC8-892E-180F340DA18C

P3181

Q24601746-18D1349A-88B2-4BF8-8AD3-125158A62347

P356

Q24601746-6D3C9ABE-9DAE-4E5A-BB41-BB214962CC69

P407

Q24601746-0119BA82-02C8-4FE1-811A-F61BAD68C10F

P433

Q24601746-7AB781D0-8705-4B22-A40F-A430E672D794

P478

Q24601746-0F06C63D-F72C-41DE-A8D9-ED42EDBC76D9

P50

Q24601746-9C64E2B5-0E3A-4507-8E0B-6219027551B6

P577

Q24601746-FEEFB417-DD37-4B7A-ADF5-2DF6723DB3E8

P5875

Q24601746-DDCE3159-9A6C-47D7-A634-D691BA77A39D

P698

Q24601746-4E7F5689-E7E4-4C61-9262-2B1B89863491

P921

Q24601746-3658C32F-59DA-4932-AD27-637BAFFFFD88

Q24601746-8616CAAC-B692-4156-9829-D94A44EF864F

P932

Q24601746-80CDE71C-E170-4CBE-9744-7C2EC17ACEAA

P3181

P356

P1433

Clinical Infectious Diseases

P1476

10 x '20 Progress--development ...... us Diseases Society of America

@en

P2093

Barbara E Murray

http://www.w3.org/2001/XMLSchema#string

Daniel K Benjamin

http://www.w3.org/2001/XMLSchema#string

David Gilbert

http://www.w3.org/2001/XMLSchema#string

George H Talbot

http://www.w3.org/2001/XMLSchema#string

Helen W Boucher

http://www.w3.org/2001/XMLSchema#string

John Bradley

http://www.w3.org/2001/XMLSchema#string

Robert J Guidos

http://www.w3.org/2001/XMLSchema#string

Ronald N Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Combating antimicrobial resistance: policy recommendations to save lives

Updated functional classification of beta-lactamases

A functional classification scheme for beta-lactamases and its correlation with molecular structure

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008.

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Antibiotics in the clinical pipeline in 2011.

P304

1685-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1488742

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/CID/CIT152

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Bonomo

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236334926

http://www.w3.org/2001/XMLSchema#string

P698

23599308

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

Gram-negative bacteria

P932

3707426

http://www.w3.org/2001/XMLSchema#string